Analyst Ratings For ADMA Biologics Inc (NASDAQ:ADMA)
Today, HC Wainwright initiated coverage on ADMA Biologics Inc (NASDAQ:ADMA) with a Buy with a price target of $10.00.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on ADMA Biologics Inc (NASDAQ:ADMA) is Buy with a consensus target price of $10.4167 per share, a potential 264.22% upside.
Some recent analyst ratings include
- 2/7/2019-ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy ➝ Buy rating and $10.00 price target
- 10/12/2018-ADMA Biologics Inc (NASDAQ:ADMA) had its Buy rating reiterated by Raymond James with a $10.00 price target
- 7/30/2018-ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy rating and $10.00 price target
- On 6/8/2018 Adam S Grossman, CEO, bought 52,301 with an average share price of $4.78 per share and the total transaction amounting to $249,998.78.
- On 6/8/2018 Brian Lenz, CFO, bought 5,000 with an average share price of $4.78 per share and the total transaction amounting to $23,900.00.
- On 6/8/2018 Jerrold B Grossman, Director, bought 20,921 with an average share price of $4.78 per share and the total transaction amounting to $100,002.38.
- On 11/9/2017 Adam S Grossman, Insider, bought 485,000 with an average share price of $2.15 per share and the total transaction amounting to $1,042,750.00.
- On 11/9/2017 Brian Lenz, CFO, bought 6,500 with an average share price of $2.15 per share and the total transaction amounting to $13,975.00.
- On 11/9/2017 Eric I Richman, Director, bought 25,000 with an average share price of $2.15 per share and the total transaction amounting to $53,750.00.
- On 11/9/2017 James Mond, CMO, bought 10,000 with an average share price of $2.15 per share and the total transaction amounting to $21,500.00.
Recent Trading Activity for ADMA Biologics Inc (NASDAQ:ADMA)
Shares of ADMA Biologics Inc closed the previous trading session at 2.87 up +0.090 3.23% with 3.04 shares trading hands.